Helix BioPharma Corp. Announces Voting Results from Its Annual and Special Meeting of Shareholders
January 17, 2017 17:05 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - Jan. 17, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix"), a clinical stage immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. Announces Additional Private Placement Closing
December 30, 2016 07:30 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Dec 30, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Closes Private Placement
December 29, 2016 08:15 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Dec 29, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Successfully Out-Licenses Late Stage Biphasix Technology
December 23, 2016 07:45 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Dec 23, 2016) - Helix BioPharma Corp. ("Helix" or the "Company") (TSX: HBP) (FRANKFURT: HBP), a clinical-stage, immuno-oncology company developing innovative drug...
Helix BioPharma Corp. Announces the Signing of a Non-Binding Letter of Intent With ProMab Biotechnologies to Develop Cell Based Therapies
December 22, 2016 07:45 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Dec 22, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Announces Fiscal First Quarter 2017 Results
December 13, 2016 19:46 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - Dec. 13, 2016) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of...
Helix BioPharma Corp. to Present at the Biotech Showcase Conference During the Annual JP Morgan Week in San Franscisco
December 09, 2016 20:10 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Dec 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Presents Topline L-DOS47 Results at the 17th IASCLC World Conference on Lung Cancer
December 06, 2016 08:30 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Dec 6, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the U.S. Phase I Study
November 30, 2016 07:30 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Nov 30, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Announces Poster Presentation of L-DOS47 at the World Conference on Lung Cancer
November 17, 2016 08:00 ET
|
Helix BioPharma Corp.
TORONTO, ON--(Marketwired - Nov 17, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and...